Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $71.6 million.

  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities rose 1501.05% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 1501.05%. This contributed to the annual value of $68.5 million for FY2024, which is 4438.23% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Total Non-Current Liabilities of $71.6 million as of Q3 2025, which was up 1501.05% from $65.1 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Total Non-Current Liabilities high stood at $71.6 million for Q3 2025, and its period low was $14.3 million during Q3 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Total Non-Current Liabilities value was $38.9 million (recorded in 2022), while the average stood at $40.0 million.
  • Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities showed a top increase of 16280.01% in 2022 and a maximum decrease of 796.38% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities (Quarter) stood at $14.8 million in 2021, then soared by 162.8% to $38.9 million in 2022, then rose by 22.03% to $47.4 million in 2023, then surged by 44.38% to $68.5 million in 2024, then increased by 4.57% to $71.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $71.6 million for Q3 2025, versus $65.1 million for Q2 2025 and $54.6 million for Q1 2025.